Recommendation of the President – Darzalex (daratumumab)
On 12 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 33/2026 regarding the inclusion of the medicinal product Darzalex (daratumumab) in the reimbursement program B.54, “Treatment of patients with multiple myeloma (ICD-10: C90.0)”